|
WO2021067854A1
|
|
Blastocyst-like structures from extended pluripotent stem cells
|
|
US2021032303A1
|
|
Fibroblast growth factor 1 (fgf1) mutant proteins that selectively activate fgfr1b to reduce blood glucose
|
|
WO2020205604A1
|
|
High-efficiency reconstitution of rna molecules
|
|
US2020199556A1
|
|
Rna targeting methods and compositions
|
|
CA3115118A1
|
|
Cells, islets and organoids that evade immune detection and autoimmunityy, methods of production and use thereof
|
|
WO2021034336A1
|
|
Compositions and methods for in vivo gene editing
|
|
US2019380336A1
|
|
Nematode deterrent compositions
|
|
WO2019199859A1
|
|
Oncolytic adenovirus compositions with enhanced replication properties
|
|
EP3724338A1
|
|
Genetically encoded fluorescent-iron ferritin nanoparticle probes for detecting an intracellular target by fluorescent and electron microscopy
|
|
US2019171665A1
|
|
Image similarity search via hashes with expanded dimensionality and sparsification
|
|
WO2019023149A1
|
|
Use of bromodomain-containing protein 9 antagonists in combination with vitamin d receptor agonists in diabetes treatment
|
|
WO2019236081A1
|
|
Targeted gene activation using modified guide rna
|
|
US2019062724A1
|
|
RNA targeting methods and compositions
|
|
US2018200379A1
|
|
Vitamin d receptor agonists to treat diseases involving cxcl12 activity
|
|
WO2018125970A1
|
|
Synthetic adenoviruses targeting bone tissue and uses thereof
|
|
US2018171305A1
|
|
Use of phospholipid scramblase inhibitors for modulating inflammatory immune responses
|
|
WO2018112200A1
|
|
Use of fibroblast growth factor 1 (fgf1)-vagus nerve targeting chimeric proteins to treat hyperglycemia
|
|
EP3532082A1
|
|
Tumor-targeting synthetic adenoviruses and uses thereof
|
|
US2018112228A1
|
|
Environmental stress response transcriptional regulatory network
|
|
WO2018026713A1
|
|
Fibroblast growth factor (fgf) 1 proteins with glucose lowering ability and reduced mitogenicity
|
